Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report

Immune checkpoint inhibitors (ICI) have been developed in gastric adenocarcinomas and approved in first-line metastatic setting (in combination with chemotherapy) as well as in pretreated patients. Microsatellite instability-high (MSI-H) tumors are predicted to derive high benefit from ICI but data...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnier, Romain, Garrivier, Thibaut, Hafliger, Emilie, Favre, Aymeric, Coutzac, Clélia, Spire, Clément, Rochefort, Pauline, Sarabi, Matthieu, Desseigne, Françoise, Guibert, Pierre, Cattey-Javouhey, Anne, Funk-Debleds, Pamela, Mastier, Charles, Buisson, Adrien, Pérol, David, Trédan, Oliver, Blay, Jean-Yves, Phelip, Jean-Marc, de la Fouchardiere, Christelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499695/
https://www.ncbi.nlm.nih.gov/pubmed/34631593
http://dx.doi.org/10.3389/fonc.2021.756365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499695/
https://www.ncbi.nlm.nih.gov/pubmed/34631593
http://dx.doi.org/10.3389/fonc.2021.756365

Ejemplares similares